Cargando…

Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

OBJECTIVE: To assess the frequency of venous thromboembolism (VTE) events in the Rituximab in Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis (RAVE) trial and identify novel potential risk factors. METHODS: VTE events in 197 patients enrolled in the RAVE trial were analyzed. Baselin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kronbichler, Andreas, Leierer, Johannes, Shin, Jae Il, Merkel, Peter A., Spiera, Robert, Seo, Philip, Langford, Carol A., Hoffman, Gary S., Kallenberg, Cees G. M., St.Clair, E. William, Brunetta, Paul, Fervenza, Fernando C., Geetha, Duvuru, Keogh, Karina A., Monach, Paul A., Ytterberg, Steven R., Mayer, Gert, Specks, Ulrich, Stone, John H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Vasculitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899947/ https://www.ncbi.nlm.nih.gov/pubmed/31216123 http://dx.doi.org/10.1002/art.41017

Ejemplares similares

Risk of relapse of ANCA-associated vasculitis among patients homozygous for the proteinase 3 gene Val119Ile polymorphism
por: Casal Moura, Marta, et al.
Publicado: (2023)

Risk factors for serious infections in ANCA-associated vasculitis
por: Odler, Balazs, et al.
Publicado: (2023)

Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
por: Merkel, Peter A., et al.
Publicado: (2017)

Immune checkpoint inhibitors as potential triggers for ANCA vasculitis
por: Aqeel, Faten, et al.
Publicado: (2022)

Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Randomized Controlled Study
por: Jayne, David, et al.
Publicado: (2019)

Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis
por: Thompson, Gwen E., et al.
Publicado: (2020)

Outcomes of COVID-19 in patients with ANCA-associated vasculitis receiving avacopan
por: Aqeel, Faten, et al.
Publicado: (2023)

Proteinase 3 promotes formation of multinucleated giant cells and granuloma-like structures in patients with granulomatosis with polyangiitis
por: Henderson, Scott R, et al.
Publicado: (2023)

Diagnostic significance of antineutrophil cytoplasmic antibody (ANCA) titres: a retrospective case-control study
por: Merindol, Julie, et al.
Publicado: (2023)

Syk Activation in Circulating and Tissue Innate Immune Cells in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Prendecki, Maria, et al.
Publicado: (2022)

Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis
por: Merkel, Peter A., et al.
Publicado: (2021)

Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody-associated vasculitis—a meta-analysis
por: Kuzuya, Kentaro, et al.
Publicado: (2020)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Circulating autoreactive proteinase 3(+) B cells and tolerance checkpoints in ANCA-associated vasculitis
por: Berti, Alvise, et al.
Publicado: (2021)

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial
por: Smith, Rona M, et al.
Publicado: (2023)

Phase IIa Global Study Evaluating Rituximab for the Treatment of Pediatric Patients With Granulomatosis With Polyangiitis or Microscopic Polyangiitis
por: Brogan, Paul, et al.
Publicado: (2021)

Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019)

Measuring treatment outcomes and change in disease activity in giant cell arteritis: a systematic literature review informing the development of the EULAR-ACR response criteria on behalf of the EULAR-ACR response criteria in giant cell arteritis task force
por: Sanchez-Alvarez, Catalina, et al.
Publicado: (2023)

Geo-epidemiology of temporal artery biopsy-positive giant cell arteritis in Australia and New Zealand: is there a seasonal influence?
por: De Smit, Elisabeth, et al.
Publicado: (2017)

Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA‐Associated Vasculitis
por: Monach, Paul A., et al.
Publicado: (2021)

Identification of new risk loci shared across systemic vasculitides points towards potential target genes for drug repurposing
por: Ortiz-Fernández, Lourdes, et al.
Publicado: (2023)

Influence of the EULAR recommendations for the use of imaging in large vessel vasculitis in the diagnosis of giant cell arteritis: results of the ARTESER register
por: De Miguel, Eugenio, et al.
Publicado: (2022)

Outcomes during and after long-term tocilizumab treatment in patients with giant cell arteritis
por: Matza, Mark A, et al.
Publicado: (2023)

Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study
por: Rutherford, Matthew A., et al.
Publicado: (2021)

Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group
por: Chrysidis, Stavros, et al.
Publicado: (2018)

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
por: Yates, Max, et al.
Publicado: (2017)

PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis
por: Lester, Susan, et al.
Publicado: (2016)

Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients
por: Prieto-González, Sergio, et al.
Publicado: (2017)

Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases
por: Izumi, Keisuke, et al.
Publicado: (2015)

Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review
por: Mackie, Sarah Louise, et al.
Publicado: (2015)

Balancing on the edge: implications of a UK national audit of the use of BSR-BHPR guidelines for the diagnosis and management of polymyalgia rheumatica
por: Das, Parthajit, et al.
Publicado: (2015)

Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis
por: Evans, Jobie, et al.
Publicado: (2016)

Long-term patient survival in a Swedish population-based cohort of patients with ANCA-associated vasculitis
por: Heijl, Caroline, et al.
Publicado: (2017)

Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis
por: Lai, Lana Yin Hui, et al.
Publicado: (2018)

T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach
por: Martinez Valenzuela, Laura, et al.
Publicado: (2019)

Treatment of polyarteritis nodosa with tocilizumab: a new therapeutic approach?
por: Saunier, Aurélie, et al.
Publicado: (2017)

Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
por: Goodfellow, Nicola, et al.
Publicado: (2017)

Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study
por: Cutolo, Maurizio, et al.
Publicado: (2017)

Vascular ultrasound for the diagnosis of giant cell arteritis: a reliability and agreement study based on a standardised training programme
por: Chrysidis, Stavros, et al.
Publicado: (2020)

Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic
por: Sebastian, Alwin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_25csvtvkfkofc6rba1oks4bfco